Evidence map›Paper›PMID 23180244›Full record

ArticleMolecular and cellular biochemistry2013

Rv3080c regulates the rate of inhibition of mycobacteria by isoniazid through FabD.

Ruma Kumari, Richa Saxena, Sameer Tiwari, Dinesh K Tripathi, Kishore K Srivastava

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Microbiology spectrum · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ruma KumariDepartment of Microbiology, CSIR-Central Drug Research Institute, Lucknow, 226001, India.
Richa Saxena
Sameer Tiwari
Dinesh K Tripathi
Kishore K Srivastava
Central Drug Research Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mycobacterial FASII multi-enzyme complex has been identified to be a target of Ser/Thr protein kinases (STPKs) of Mycobacterium tuberculosis (MTB), with substrates, including the malonyl-CoA:ACP transacylase (FabD) and the β-ketoacyl-ACP synthases KasA and KasB. These proteins are phosphorylated by various kinases in vitro. The present study links the correlation of FASII pathway with serine threonine protein kinase of MTB. In the preliminary finding, we have shown that mycobacterial protein Rv3080c (PknK) phosphorylates FabD and the knockdown of PknK protein in mycobacteria down regulates FabD expression. This event leads to the differential inhibition of mycobacteria in the presence of isoniazid (INH), as the inhibition of growth of mycobacteria in the presence of INH is enhanced in PknK deficient mycobacteria.

Indexed as

Acyl-Carrier Protein S-MalonyltransferaseAntitubercular AgentsBacterial ProteinsEscherichia coliEscherichia coli ProteinsFatty Acid Synthase, Type IIIsoniazidMycobacterium tuberculosisMycolic AcidsProtein Serine-Threonine KinasesSignal TransductionAcyl-Carrier Protein S-MalonyltransferaseAntitubercular AgentsBacterial ProteinsEscherichia coli ProteinsfabD protein, E coliFatty Acid Synthase, Type IIIsoniazidMycolic AcidsPknk protein, Mycobacterium tuberculosisProtein Serine-Threonine Kinases

Identifiers

PMID23180244
OpenAlexW2142110456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.